Compare RMCF & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCF | HSCS |
|---|---|---|
| Founded | 1981 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 15.8M |
| IPO Year | 2024 | 2022 |
| Metric | RMCF | HSCS |
|---|---|---|
| Price | $1.06 | $3.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 88.7K | ★ 146.6K |
| Earning Date | 10-20-2026 | 09-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.88 | ★ 50.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,432,352.00 | $4,319.00 |
| Revenue This Year | N/A | $295.93 |
| Revenue Next Year | N/A | $18,321.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $1.63 |
| 52 Week High | $2.99 | $5.25 |
| Indicator | RMCF | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 42.40 |
| Support Level | $0.84 | $1.84 |
| Resistance Level | $1.19 | $3.67 |
| Average True Range (ATR) | 0.08 | 0.45 |
| MACD | 0.03 | -0.20 |
| Stochastic Oscillator | 47.21 | 10.50 |
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.